Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Waxrim is a topical otic formulation developed and marketed by Chethana Pharmaceuticals, primarily indicated for the softening and removal of dry or hardened ear wax (cerumen). The active ingredient is dioctyl sodium sulfosuccinate (also known as docusate sodium) at a concentration of 0.5% w/v. As a surfactant, it functions as a cerumenolytic by reducing the surface tension at the wax-water interface, which allows moisture to penetrate and soften the impacted wax. This action facilitates the natural migration of wax out of the ear canal or simplifies clinical removal procedures. The product is formulated as ear drops for external use and contains methylparaben as a preservative.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Waxrim.